Leading BioSciences, Inc   Report issue

For profit Phase 1 Phase 2
Founded: Solana Beach CA United States (2005)
Status: Acquired by Seneca Biopharma, Inc. (2021)

Organization Overview

First Clinical Trial
2012
NCT01683747
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Inflammagen | Inflammagen/Leading Ventures | Leading BioSciences, Inc | Shanxi Zhendong Leading Biotechnology Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

Key: Leading BioSciences, Inc (0) Acquired (2)

nsi-189 (3 trials)

tranexamic acid (cyklokapron) (4 trials)

Drugs in Phase 1 Trials (4)

Key: Leading BioSciences, Inc (0) Acquired (4)

cellulose (1 trial)

human spinal cord stem cells (1 trial)

nsi-566 (1 trial)

zd03 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Critical Illness (Phase 2)

Hypotension (Phase 2)

Ileus (Phase 2)

Pneumonia (Phase 2)

Shock (Phase 2)

Shock, Septic (Phase 2)

Tissue Adhesions (Phase 2)

Overview

  • Highest Phase: None
  • # of Trials: 10
  • # of Trial APIs: 6